Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VBI Vaccines Inc VBIVQ

Healthcare Biotechnology
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The... see more

Recent & Breaking News (GREY:VBIVQ)

VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

GlobeNewswire October 12, 2022

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

Business Wire September 29, 2022

VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting

Business Wire September 21, 2022

VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures

Business Wire September 15, 2022

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Business Wire September 8, 2022

VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Business Wire August 8, 2022

VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer

Business Wire July 12, 2022

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022

Business Wire June 28, 2022

VBI Vaccines Announces Results of Annual General Meeting

Business Wire June 22, 2022

VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

Business Wire June 22, 2022

VBI Vaccines to Participate in the Jefferies Healthcare Conference

Business Wire June 7, 2022

VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting

Business Wire June 6, 2022

VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri(TM), a 3-Antigen Adult Hepatitis B Vaccine

Business Wire June 1, 2022

VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022

Business Wire May 26, 2022

VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio(TM) at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022

Business Wire May 19, 2022

VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update

Business Wire May 9, 2022

VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri(TM), a 3-Antigen Adult Hepatitis B Vaccine

Business Wire May 2, 2022

VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual Meeting

Business Wire April 28, 2022

VBI Vaccines Announces New Data and Progress of VBI-2900, VBI's eVLP Coronavirus Program

Business Wire April 5, 2022

VBI Vaccines Announces PreHevbrio(TM) is Now Available in the United States for the Prevention of Hepatitis B in Adults

Business Wire March 29, 2022